...
  • 主题
高级搜索  >
历史搜索 清空历史
首页> 外文期刊>The journal of clinical psychiatry >The effects of olanzapine on the 5 dimensions of schizophrenia derived by factor analysis: combined results of the North American and international trials.
【24h】

The effects of olanzapine on the 5 dimensions of schizophrenia derived by factor analysis: combined results of the North American and international trials.

机译：通过因子分析得出奥氮平对精神分裂症5个方面的影响：北美和国际试验的合并结果。

获取原文
获取原文并翻译 | 示例
           
页面导航
  • 摘要
  • 著录项
  • 相似文献
  • 相关主题

摘要

BACKGROUND: The choice of drug to treat a patient with schizophrenia is one of the most critical clinical decisions. Controversy exists on the differential efficacy of olanzapine. DATA SOURCES AND STUDY SELECTION: Raw data from all 4 registrational double-blind, random-assignment studies of olanzapine compared with placebo or haloperidol were obtained from Eli Lilly and Company for this meta-analysis. METHOD: Analysis of covariance of the intent-to-treat last-observation-carried-forward endpoint scores was used to assess efficacy on Brief Psychiatric Rating Scale (BPRS) and Positive and Negative Syndrome Scale (PANSS) total scores and the 5 factors derived by factor analysis (negative symptoms, positive symptoms, disorganized thoughts, impulsivity/hostility, and anxiety/depression). RESULTS: Olanzapine produced a statistically significantly greater reduction in schizophrenic symptoms than haloperidol (p < .05) on total scores on the BPRS and PANSS on each of the 5 factors as well as on almost all items. Olanzapine induced a response at a rate equal to that induced by haloperidol in the first few weeks, but by the end of the study produced a greater percentage of responders. Compared with haloperidol, olanzapine produced a somewhat greater response on symptoms responsive to haloperidol, but a markedly better response on symptoms unresponsive to haloperidol. This difference favoring olanzapine occurred to an equal degree in all subgroups examined. The incidence of parkinsonism or akathisia following olanzapine treatment was extremely low and not statistically distinguishable from placebo. CONCLUSION: Olanzapine produced a greater improvement than haloperidol particularly by benefiting a much larger number of items or factors. Extrapyramidal side effects and akathisia during olanzapine treatment were statistically indistinguishable from effects seen with placebo.
机译：背景：治疗精神分裂症患者的药物选择是最关键的临床决策之一。关于奥氮平的疗效差异存在争议。数据来源和研究选择：来自Elan Lilly和Company的所有4项奥氮平注册双盲，随机分配研究与安慰剂或氟哌啶醇相比的原始数据用于这项荟萃分析。方法：采用意向治疗最后观察携带前瞻性终点评分的协方差分析，以简短精神病学量表（BPRS）和阳性和阴性综合征量表（PANSS）总分以及5项衍生因素评估疗效通过因素分析（消极症状，积极症状，思想混乱，冲动/敌意和焦虑/抑郁）。结果：在5个因素以及几乎所有项目的BPRS和PAN​​SS总分上，奥氮平在精神分裂症症状方面的减少均显着大于氟哌啶醇（p <.05）。在最初的几周内，奥氮平诱发的反应速率与氟哌啶醇相同，但到研究结束时，产生了更大比例的反应。与氟哌啶醇相比，奥氮平对氟哌啶醇有反应的症状产生了更大的反应，但对氟哌啶醇无反应的症状有明显更好的反应。在所有检查的亚组中，这种有利于奥氮平的差异均发生在相同的程度。奥氮平治疗后的帕金森氏症或静坐症的发生率极低，与安慰剂无统计学差异。结论：奥氮平比氟哌啶醇产生了更大的改善，特别是受益于大量的项目或因素。奥氮平治疗期间的锥体外系副作用和静坐无理与安慰剂所见无统计学差异。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱：kefu@zhangqiaokeyan.com

京公网安备：11010802029741号 ICP备案号：京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有

  • 客服微信

  • 服务号